2019冠状病毒病大流行背景下的银屑病和银屑病关节炎：来自GRAPPA 2020年会的全会报告

Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting.

作者信息

Mease Philip J, Calabrese Leonard H, Callis Duffin Kristina, Haberman Rebecca H, Firmino Rodrigo, Scher Jose U, Schick Lori, Winthrop Kevin, Merola Joseph F

机构信息

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women's Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email:

出版信息

J Rheumatol. 2021 Mar 15. doi: 10.3899/jrheum.201671.

DOI:10.3899/jrheum.201671

PMID:33722951

Abstract

The coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic has affected the healthcare system on a global scale, and we utilized the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 annual meeting to examine how COVID-19 might affect patients with psoriatic disease (PsD) and the clinicians who care for them. Pressing issues and concerns identified included whether having psoriasis increased the risk of acquiring COVID-19, vaccine safety, and the acceptability of telehealth. The general message from rheumatologists, dermatologists, infectious disease specialists, and patient research partners was that data did not suggest that having PsD or its treatment significantly increased risk of infection or more severe disease course, and that the telehealth experience was a success overall.

摘要

2019年冠状病毒病（COVID-19；由严重急性呼吸综合征冠状病毒2型[SARS-CoV-2]引起）大流行在全球范围内影响了医疗保健系统，我们利用银屑病和银屑病关节炎研究与评估小组（GRAPPA）2020年年会来研究COVID-19如何影响银屑病患者（PsD）以及照料他们的临床医生。确定的紧迫问题和担忧包括患银屑病是否会增加感染COVID-19的风险、疫苗安全性以及远程医疗的可接受性。风湿病学家、皮肤科医生、传染病专家和患者研究合作伙伴传达的总体信息是，数据并未表明患有PsD或其治疗会显著增加感染风险或导致更严重的病程，并且远程医疗体验总体上是成功的。